Werewolf Therapeutics, Inc. reported a diluted loss of -$0.20 per share for the fourth quarter of 2025, representing a 56.5% improvement from the -$0.46 per share loss recorded in the same period last year. The biopharmaceutical company, which focuses on developing therapeutics engineered to stimulate the body’s immune system for cancer treatment, posted a net loss of $8.4M for the quarter.
The Cambridge-based biotech generated $0 in revenue for the quarter, consistent with its development-stage status as it advances its pipeline of immune-stimulating therapeutics. The company specializes in creating treatments designed to harness the body’s natural defenses against cancer and other immune-mediated conditions.
Despite operating in the cash-intensive phase of drug development, Werewolf Therapeutics has maintained support from the analyst community. Wall Street consensus currently stands at 9 buy ratings, 3 hold ratings, and 0 sell recommendations for the NASDAQ-traded stock. The narrowing of losses year-over-year reflects the company’s efforts to manage its burn rate while progressing its clinical programs.
A detailed analysis of Werewolf Therapeutics, Inc.’s quarter follows shortly on AlphaStreet.
This article was generated with the assistance of AI technology and reviewed for accuracy. AlphaStreet may receive compensation from companies mentioned in this article. This content is for informational purposes only and should not be considered investment advice.